Methods and systems for modifying bioactive agent use

Patent metadata

Field	Value
Publication number	US-9282927-B2
Application number	US-22953108-A
Country	US
Kind code	B2
Filing date	Aug 22, 2008
Priority date	Apr 24, 2008
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

Methods, computer program products, and systems are described that include measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and/or modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect.

First claim

What is claimed is:

1. A combination treatment system comprising:
at least one in vivo type administration unit that includes at least
at least one housing;
at least one reservoir within the at least one housing and that is operable to contain at least one antidepressant agent;
at least one controllable valve or pump mechanism operable to transfer the at least one antidepressant agent from the at least one reservoir for delivery to at least one bodily site;
at least one wireless receiver operable to receive one or more wirelessly transmitted instructions; and
at least one controller communicably linked with the at least one wireless receiver and that at least one controllable valve or pump mechanism, which at least one controller is operable to control the at least one controllable valve or pump mechanism to deliver one or more dosages of the at least one antidepressant agent in accordance with one or more wirelessly transmitted instructions received by the at least one wireless receiver; and

at least one smartphone device communicably linked with the at least one administration unit, the at least one smartphone device including at least:
at least one sensor for monitoring visual appearance of an individual;
at least one wireless transmitter operable to communicate wirelessly with the at least one administration unit;
at least one display;
one or more media including one or more executable instructions; and
at least one processor operatively connected to the one or more media, wherein the at least one processor is configured to execute the one or more executable instructions to perform operations including at least:
monitoring appearance of the individual using the at least one sensor;
detecting at least one depression symptom of the individual based at least partly on monitored appearance of the individual which deviates from one or more specified levels of normalcy for the individual;
transmitting one or more instructions wirelessly to the at least one administration unit that control the at least one controllable valve or pump mechanism to deliver one or more dosages of the at least one antidepressant agent to at least one bodily site at least partly in response to detection of the at least one depression symptom of the individual based at least partly on monitored appearance of the individual which deviates from one or more specified levels of normalcy for the individual; and
implementing one or more modifications to at least one interpersonal interaction application at one or more staggered times relative to administration of the at least one antidepressant agent based at least partly on one or more pharmacokinetic profiles of the at least one antidepressant agent, the one or more staggered times corresponding to when the antidepressant agent is expected to be least effective.

2. A treatment system comprising:
a smartphone device communicably linked with an administration unit that includes at least a controllable delivery mechanism operable to control delivery of a medication, a wireless communication unit operable to receive one or more instructions, and a controller communicably linked with the wireless communication unit for controlling the delivery mechanism at least partly in response to one or more wirelessly received instructions,
wherein the smartphone device includes at least:
an input device for receiving one or more inputs of an individual;
a wireless communication unit operable to communicate wirelessly with the administration unit;
a storage medium including one or more executable instructions; and
a processor operatively connected to the storage medium, wherein the processor is configured to execute the one or more executable instructions to perform operations including at least:
receiving one or more inputs of an individual using the input device, which one or more inputs indicate a symptom;
transmitting one or more instructions wirelessly to the administration unit to control delivery of one or more dosages of the medication; and
implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication.

3. The system of claim 2 , wherein implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication comprises:
implementing one or more sound aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication.

4. The system of claim 2 , wherein the implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication comprises:
implementing one or more visual aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication.

5. The system of claim 2 , wherein the implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication comprises:
implementing one or more aspects of an application on the smartphone device at a time when the medication is expected to be least effective.

6. The system of claim 2 , wherein the processor is configured to execute the one or more executable instructions to further perform an operation including at least:
providing at least one artificial sensory experience at a specified time relative to administration of the medication.

7. The system of claim 2 , wherein the processor is configured to execute the one or more executable instructions to further perform an operation including at least:
determining one or more modifications to dosage of the medication.

8. The system of claim 2 , wherein the processor is configured to execute the one or more executable instructions to further perform an operation including at least:
selecting at least one artificial sensory experience based at least partly on monitored computer usage history of the individual.

9. The system of claim 2 , wherein the implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication comprises:
implementing one or more aspects of an application on the smartphone device at a time that corresponds with peak effect of the medication.

10. The system of claim 2 , wherein the implementing one or more aspects of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication comprises:
altering access to at least one photo of specified subject matter of an application on the smartphone device at a staggered time relative to administration of the medication based at least partly on a specified effect of the medication.

11. The system of claim 2 , further comprising:
one or more eyeglasses wearable by the individual that are operable to monitor one or more visible aspects of the individual.

12. The system of claim 2 , further comprising:
at least one nasal administration unit configured to release one or more medications for nasal administration to the individual.

13. The system of claim 2 , further comprising:
at l

Assignees

• Hyde Roderick A
• Ishikawa Muriel Y
• Leuthardt Eric C
• Levien Royce A
• Lord Robert W
• Malamud Mark A
• Sweeney Elizabeth A
• Wood Jr Lowell L
• Wood Victoria Y H
• Invention Science Fund I Llc

Inventors

• Hyde Roderick A
• Ishikawa Muriel Y
• Leuthardt Eric C
• Levien Royce A
• Lord Robert W
• Malamud Mark A
• Sweeney Elizabeth A
• Wood Jr Lowell L
• Wood Victoria Y H

Classifications

• A61B5/48 Primary

  Other medical applications · CPC title

• A61B5/418

  lymph vessels, ducts or nodes · CPC title

• A61B5/415

  the glands, e.g. tonsils, adenoids or thymus · CPC title

• A61B5/416

  the spleen · CPC title

• A61B5/05

  Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves (measuring movement of the entire body or parts thereof A61B5/11; detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof A61B5/24) · CPC title